Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

Paediatric Respiratory Reviews

Volumn 10, Issue 3, 2009, Pages 148-153

  Resch, Bernhard ^a   Manzoni, Paolo ^b   Lanari, Marcello ^c  

^a Division of Neonatology   (Austria)

^b S ANNA HOSPITAL   (Italy)

^c Hospital of Imola   (Italy)

Author keywords

immune deficiency syndromes; lower respiratory tract infection; neuromuscular diseases; palivizumab; respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BREATHING MUSCLE; CELLULAR IMMUNODEFICIENCY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COUGHING; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSPHAGIA; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNE DEFICIENCY; INFANT MORTALITY; LOWER RESPIRATORY TRACT INFECTION; LUNG DISEASE; MORBIDITY; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; PULMONARY ASPIRATION; RESPIRATORY FUNCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TREATMENT INDICATION; VIRUS INFECTION; VIRUS SHEDDING;

COMORBIDITY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; NEUROMUSCULAR DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 67849084667     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2009.06.003     Document Type: Review

References (53)

1. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344 (2001) 1917-1928
2. Glezen W.P., Taber L.H., Frank A.L., Kasel, et al. Risk of primary infection and reinfection with respiratory-syncytial virus. AJDC 140 (1986) 543-546
3. Resch B. Palivizumab for the prophylaxis of respiratory syncytial virus infection. Pediatric Health 2 (2008) 265-278
4. The, IMpact-RSV. Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
5. Feltes T.F., Cabalka A.K., Meissner C., et al. Palivizumab prophylaxis reduces hospitalisation due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143 (2003) 532-540
6. American Academy of Paediatrics: Prevention of respiratory syncytial virus infections: indications for use of of palivizumab and update on the use of RSV-IGIV. Paediatrics 1998; 102:1211-1216.
7. American Academy of Pediatrics. Revised indications for the use of palivizumab and RSV-IGIV for the prevention of respiratory syncytial virus infection. Pediatrics 2003; 112: 1442-1446 and 1447-1452.
8. Resch B., Berger A., Urlesberger B., et al. Österreichische Empfehlungen zur RSV Prophylaxe bei Frühgeborenen mit Palivizumab - Update 2003. Monatschr Kinderheilkd 152 (2004) 223-224
9. Raccomandazioni della Societa' Italiana di Neonatologia per la prevenzione delle malattie da VRS. Aggiornamento 2004 (redatto a cura del Consiglio Direttivo della SIN). Acta Neonatologica & Pediatrica 2004; 18: 19-29.
10. Simoes E.A.F. Respiratory syncytial virus infection. Lancet 354 (1999) 847-852
11. MacDonald N.E., Hall C.B., Suffin S.C., et al. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 307 (1982) 397-400
12. Navas L., Wang E.E.L., de Carvalho V., et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J Pediatr 121 (1992) 348-354
13. Altman C.A., Englund J.A., Demmler G., et al. Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of pre-operative screening. Pediatr Cardiol 21 (2000) 433-438
14. Sampalis J.S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 143 (2003) S150-S156
15. Chevret L., Mbieleu B., Essouri S., et al. Bronchiolitis treated with mechanical ventilation: prognosis factor and outcome in a series of 135 children. Arch Pediatr 12 (2005) 385-390
16. Wolff D.S., and Fiedelman W.M. Respiratory syncytial virus and asthma: is there a link?. J Pediatr Pharm Pract 4 (1999) 23-30
17. Sigurs N., Gustafsson P.M., Bjarnason R., et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 171 (2005) 137-141
18. Korppi M., Piippo-Savolainen E., Korhonen K., et al. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol 38 (2004) 155-160
19. Arnold S.R., Wang E.E., Law B.J., et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18 (1999) 866-869
20. Panitch H.B. Viral respiratory infections in children with technology dependence and neuromuscular disorders. Pediatr Infect Dis J. 23 11 Suppl (2004) S222-S227
21. Wilkesmann A., Ammann R.A., Schildgen O., et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26 (2007) 485-491
22. Millner M.E., de la Monte S.M., and Hutchins G.M. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndromes. Am J Dis Child 139 (1985) 1111-1114
23. Hall C.B., Powell K.R., MacDonald N.E., et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 315 2 (1986) 77-81
24. Chandwani S., Borkowsky W., Krasinski K., et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. J Pediatr. 117 2 Pt 1 (1990 Aug) 251-254
25. King J.C., Burke A.R., Clemens J.D., et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 12 (1993) 733-739
26. Schneider S., and Borzy M.S. Fatal respiratory syncytial virus pneumonia as the presenting feature of severe combined immunodeficiency disease. Clin Pediatr (Phila) 35 (1996) 147-149
27. Madhi S.A., Schoub B., Simmank K., et al. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 137 (2000) 78-84
28. Piehler J.M., Pairolero P.C., Gracey D.R., et al. Unexplained diaphragmatic paralysis: a harbinger of malignant disease?. J Thorac Cardiovasc Surg 84 (1982) 861-864
29. Hutchinson D., and Whyte K. Neuromuscular disease and respiratory failure. Pract Neurol 8 (2008) 229-237
30. Seddon P.C., and Khan Y. Respiratory problems in children with neurological impairment. Arch Dis Child 88 (2003) 75-78
31. Kirk C.B. Is the frequency of recurrent chest infections, in children with chronic neurological problems, reduced by prophylactic azithromycin?. Arch Dis Child 93 (2008) 442-444
32. Schechter M.S. Airway clearance applications in infants and children. Respir Care 52 (2007) 1382-1390
33. Hirschtick R.E., Glassroth J., Jordan M.C., et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus infection. The Pulmonary Complications of HIV Infection Study Group. N Engl J Med 333 (1995) 431-440
34. Schauer U. Respiratory problems in the immune-compromised host. Pediatr Allergy Immunol 7 (1996) 82-85
35. Deerojanawong J., Chang A.B., Eng P.A., et al. Pulmonary Diseases in Children with Severe Combined Immune Deficiency and DiGeorge Syndrome. Pediatric Pulmonology 24 (1997) 324-330
36. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus (RSV) infection. Arch Dis Child 2008 as 10.2236/adc.2008.139188 online first.
37. Lauzon D., Delage G., Brochu P., et al. Pathogens in children with severe combined immune deficiency disease or AIDS. CMAJ. 135 (1986 July 1) 33-38
38. Delage G., Brochu P., Robillard L., et al. Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome. Arch Pathol Lab Med. 108 8 (1984 Aug) 623-625
39. Milner M.E., de la Monte S.M., and Hutchins G.M. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome. Am J Dis Child. 139 (1985 Nov) 1111-1114
40. Padman R., Bye M.R., Schidlow D.V., et al. Severe RSV bronchiolitis in an immuno-compromised child. Clin Pediatr (Phila). 24 (1985 Dec) 719-721
41. Taylor C.E., Osman H.K., Turner A.J., et al. Parainfluenza virus and respiratory syncytial virus infection in infants undergoing bone marrow transplantation for severe combined immunodeficiency. Commun Dis Public Health. 1 3 (1998 Sep) 202-203
42. Wallace J.M. Pulmonary infection in human immunodeficiency disease: viral pulmonary infections. Semin Respir Infect. 4 2 (1989 Jun) 147-154
43. Madhi S.A., Venter M., Madhi A., et al. Differing manifestations of respiratory syncytial viral-associated severe lower respiratory tract infections in human immunodeficiency virus type-1 infected and uninfected children. Pediatr Infect Dis J 20 (2001) 164-170
44. Wang E.E.L., Law B.J., Stephens D., et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial virus lower respiratory tract infection. J Pediatr 126 (1995) 212-219
45. El Saleeby C.M., Somes G.W., DeVincenzo J.P., et al. Risk Factors for Severe RSV Disease in Children with Cancer: The Importance of Lymphopenia and Young Age. Pediatrics 121 (2008) 235-243
46. Bloemers B.L., van Furth A.M., Weijerman M.E., et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis-a prospective birth-cohort study. Pediatrics. 120 (2007) e1076-e1081
47. Blanchard S.S., Gerrek M.S.C., and Czinn S.J. Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: Case report and discussion regarding need of routine prophylaxis. Pediatric Transplant 10 (2006) 826-829
48. Boeckh M., Berrey M.M., Bowden R.A., et al. Phase I evaluation of respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplantation. J Infect Dis 184 (2001) 350-354
49. Manzoni P., Leonessa M.L., Farina D., et al. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: The experience of a large Italian neonatal care setting. Pediatr Transplantation 11 (2007) 456-457
50. Speer M., Cohen A., Boron M., et al. Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities and neuromuscular disease (abstract). Pediatr Res 55 (2004) 237A-238A
51. Cohen AH, Bomar R, Cohen LE, et al.. RSV prophylaxis using palivizumab in 86 high-risk children, outside of AAP red book Guidelines. APS/SPR/APA 2001 Convention. April 28, 2001.(Abstr. #2656).
52. Resch B., Berger A., Bernert G., et al. Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr Kinderheilkd 156 (2008) 381-383
53. Giebels K., Marcotte J.E., Podoba J., et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 43 (2008) 169-174